What it's for (Indications)
- Heparin sodium is a widely utilized anticoagulant indicated for the prophylaxis and treatment of various thromboembolic disorders.
- Key indications include the prevention and treatment of venous thrombosis, pulmonary embolism, and peripheral arterial embolism.
- It is also an essential agent in the management of acute coronary syndromes, such as unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI), often used in conjunction with other antiplatelet therapies or thrombolytics.
- Furthermore, heparin is crucial as an anticoagulant during extracorporeal circulation procedures, including cardiopulmonary bypass and hemodialysis, to prevent clotting within the circuit.
- It is employed in the prevention of cerebral thrombosis in evolving stroke (though its role here requires careful consideration due to bleeding risks) and as an adjunct in the treatment of disseminated intravascular coagulation (DIC), emphasizing its broad application in conditions requiring urgent anticoagulation.
- Its use ensures the fluidity of blood flow and prevents pathological clot formation, making it a cornerstone in cardiovascular and critical care medicine.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Heparin dosage is highly individualized and must be adjusted based on patient weight, renal function, clinical indication, and rigorous laboratory monitoring to achieve therapeutic efficacy while minimizing bleeding risk. For prophylaxis of venous thromboembolism, typical subcutaneous (SC) doses are 5,000 units every 8 to 12 hours. For therapeutic anticoagulation, common intravenous (IV) regimens include an initial IV bolus of 80 units/kg (or 5,000 units) followed by a continuous IV infusion of 18 units/kg/hour (or 1,000 units/hour). Dosage adjustments for continuous infusions are guided by activated partial thromboplastin time (aPTT) values, aiming for a target range that is typically 1.5 to 2.5 times the control value, or by anti-Factor Xa levels. In procedures like cardiopulmonary bypass, initial doses may range from 300-400 units/kg IV. For hemodialysis, an initial bolus followed by intermittent boluses or a continuous infusion is common. Regular monitoring of platelet count is imperative due to the risk of heparin-induced thrombocytopenia (HIT). Careful titration and continuous assessment are critical for safe and effective use. |
Safety & Warnings
Common Side Effects
- Heparin, while life-saving, is associated with a range of side effects, the most significant being hemorrhage.
- Bleeding can manifest in various forms, from minor bruising and injection site hematomas to severe, life-threatening events such as gastrointestinal bleeding, intracranial hemorrhage, retroperitoneal hemorrhage, hematuria, or epistaxis.
- Patients must be vigilantly monitored for any signs of bleeding.
- A severe and paradoxical complication is Heparin-Induced Thrombocytopenia (HIT), an immune-mediated adverse drug reaction that can lead to a hypercoagulable state and thrombotic events (HITT), even after heparin discontinuation.
- Other serious but less common side effects include hypersensitivity reactions (e.
- g.
- , urticaria, pruritus, fever, chills, anaphylaxis), skin necrosis, and adrenal hemorrhage.
- Long-term use (typically beyond one month) can contribute to osteoporosis, especially with higher doses.
- Hyperkalemia can also occur due to aldosterone suppression.
- Patients should be educated on recognizing potential adverse effects and seeking immediate medical attention if they occur.
Serious Warnings
- Black Box Warning: Despite its critical role, heparin carries significant risks, and prescribers must be acutely aware of two paramount dangers: severe, potentially fatal hemorrhage and the unique immunological complication of Heparin-Induced Thrombocytopenia (HIT). **1. Risk of Major Hemorrhage:** Heparin administration can lead to severe and life-threatening bleeding, which may be fatal. This risk is amplified in patients with pre-existing conditions that increase hemorrhagic propensity, such as active bleeding, recent surgery, trauma, peptic ulcer disease, hemorrhagic stroke, or severe uncontrolled hypertension. Concurrent use of other medications affecting hemostasis (e.g., antiplatelet agents, other anticoagulants, thrombolytics) further elevates this risk. Patients must be carefully monitored for signs of bleeding (e.g., hematuria, melena, ecchymosis, epistaxis, or sudden neurological changes indicative of intracranial hemorrhage), and laboratory parameters such as aPTT, hemoglobin, and hematocrit should be routinely assessed. Protamine sulfate is the antidote for heparin overdose. **2. Heparin-Induced Thrombocytopenia (HIT):** Heparin can cause an immune-mediated adverse reaction known as Heparin-Induced Thrombocytopenia (HIT), which can be severe and life-threatening. HIT is characterized by a significant decrease in platelet count (typically a fall of >50% from baseline or to below 100,000/mm³) occurring 5-10 days after heparin initiation, though it can occur earlier with prior heparin exposure. Paradoxically, HIT is associated with a high risk of new or recurrent thrombotic events, known as Heparin-Induced Thrombocytopenia with Thrombosis (HITT), which can affect both arterial and venous systems. All patients receiving heparin must have their platelet counts monitored regularly (e.g., every 2-3 days from Day 4 to 14, or until heparin is discontinued). If HIT is strongly suspected, heparin must be immediately discontinued, and alternative non-heparin anticoagulation (e.g., argatroban, bivalirudin) should be initiated. Heparin must not be re-administered to patients with a history of HIT.
- Heparin carries substantial risks that necessitate careful consideration and vigilant monitoring.
- The primary warning concerns the profound risk of hemorrhage, which can be fatal.
- Patients at increased risk include those with recent surgery, trauma, active ulcer disease, hemorrhagic stroke, uncontrolled hypertension, or severe hepatic or renal impairment.
- Co-administration with other antiplatelet agents (e.
- g.
- , aspirin, NSAIDs) or anticoagulants significantly amplifies bleeding risk.
- A critical and potentially devastating warning is the risk of Heparin-Induced Thrombocytopenia (HIT), an immune-mediated disorder characterized by a significant drop in platelet count (typically >50% from baseline) and a paradoxical increased risk of thrombosis.
- Platelet counts must be monitored frequently (e.
- g.
- , every 2-3 days from Day 4 to 14, or until heparin is discontinued).
- If HIT is suspected, heparin must be immediately discontinued, and alternative non-heparin anticoagulation initiated.
- Furthermore, there is an increased risk of spinal or epidural hematomas in patients undergoing neuraxial anesthesia or spinal puncture while on heparin, which can result in long-term or permanent paralysis.
- Elderly patients and those with impaired renal or hepatic function are at increased risk of bleeding and require closer monitoring and potential dose adjustments.
- Hypersensitivity reactions, including anaphylaxis, can occur and require immediate intervention.
How it Works (Mechanism of Action)
Heparin's anticoagulant properties stem from its ability to enhance the activity of antithrombin (AT), a naturally occurring plasma protein that inactivates several coagulation enzymes. Heparin, a highly sulfated glycosaminoglycan, binds to antithrombin, causing a conformational change that increases antithrombin's affinity for and acceleration of the inactivation of activated clotting factors, most notably thrombin (Factor IIa) and Factor Xa. The binding of heparin to AT leads to an approximately 1,000-fold increase in the rate at which AT inactivates these factors. Specifically, heparin forms a ternary complex with AT and thrombin, leading to thrombin inactivation. For Factor Xa, heparin primarily acts as a catalyst by binding to AT and FXa simultaneously, accelerating FXa's inactivation by AT. By inactivating thrombin, heparin prevents the conversion of fibrinogen to fibrin, thereby inhibiting the formation of a stable clot. The inactivation of Factor Xa also disrupts the common pathway of coagulation, further impeding clot formation. Unfractionated heparin, due to its varied chain lengths, effectively catalyzes the inactivation of both thrombin and Factor Xa. It does not directly lyse existing clots but prevents their extension and new clot formation.